Compare AIRT & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRT | NBP |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 96.0M |
| IPO Year | 2018 | 2019 |
| Metric | AIRT | NBP |
|---|---|---|
| Price | $21.54 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 24.5K | ★ 526.3K |
| Earning Date | 11-13-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1393.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $286,834,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.98 | N/A |
| 52 Week Low | $18.40 | $0.75 |
| 52 Week High | $35.00 | $5.19 |
| Indicator | AIRT | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 27.37 | 30.80 |
| Support Level | $20.22 | N/A |
| Resistance Level | $23.74 | $1.45 |
| Average True Range (ATR) | 1.78 | 0.07 |
| MACD | -0.60 | 0.01 |
| Stochastic Oscillator | 18.01 | 31.05 |
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include overnight air cargo, ground support equipment, commercial aircraft, engines and parts, digital solutions, and regional airline. The company generates maximum revenue from the overnight air cargo segment.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.